Origami B Competent Cells - Novagen

Genotype: F^-ompT hsdS_B(r_B^- m_B^-) gal dcm lacY1 ahpC gor522::Tn10 trxB (Kan^R, Tet^R)

This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.

Origami B host strains carry the same trxB/gor mutations as the original Origami strains, except that they are derived from a lacZY mutant of BL21. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner and Origami hosts in one strain background. The trxB and gor mutations are selectable on kanamycin and tetracycline, respectively; therefore, these strains are recommended for use only with pET plasmids carrying the ampicillin resistance marker bla.

Origami B host strains carry the same mutations as the original Origami strain, except that they are derived from a lacZY mutant of BL21 to enable precise control of expression levels using IPTG.

0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlOrigami B Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•10 µl10 µlTest Plasmid

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Multiple Toxicity Values, refer to MSDS (O)